XORTX Therapeutics Inc
XRTX0.400USD
-0.002-0.40%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
2.09MMarket Cap
LossP/E TTM
More Details of XORTX Therapeutics Inc Company
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
XORTX Therapeutics Inc Info
Ticker SymbolXRTX
Company nameXORTX Therapeutics Inc
IPO dateSep 30, 2015
CEODavidoff (Allen W)
Number of employees2
Security typeOrdinary Share
Fiscal year-endSep 30
Address3710 - 33rd Street NW
CityCALGARY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeT2L 2M1
Phone14034557727
Websitehttps://www.xortx.com/
Ticker SymbolXRTX
IPO dateSep 30, 2015
CEODavidoff (Allen W)
Company Executives of XORTX Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Feb 6
Updated: Fri, Feb 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
Baader Bank AG
0.27%
XTX Markets LLC
0.20%
Other
88.34%
Shareholders
Shareholders
Proportion
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
Baader Bank AG
0.27%
XTX Markets LLC
0.20%
Other
88.34%
Shareholder Types
Shareholders
Proportion
Corporation
8.22%
Individual Investor
1.91%
Hedge Fund
1.24%
Investment Advisor/Hedge Fund
0.27%
Venture Capital
0.20%
Investment Advisor
0.03%
Other
88.13%
Institutional Shareholding
Updated: Wed, Jan 21
Updated: Wed, Jan 21
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
10
101.02K
4.75%
--
2025Q4
16
102.18K
1.47%
-649.58K
2025Q3
16
63.97K
1.23%
-645.66K
2025Q2
17
129.44K
3.30%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lincoln Alternative Strategies LLC
572.47K
8.22%
+572.47K
--
Oct 23, 2025
Davidoff, Allen Warren
120.45K
1.73%
+8.19K
+7.30%
Jul 22, 2025
Citadel Advisors LLC
86.33K
1.24%
+47.86K
+124.41%
Sep 30, 2025
XTX Markets LLC
13.82K
0.2%
+13.82K
--
Sep 30, 2025
Giovinazzo (Anthony)
9.63K
0.14%
--
--
Apr 30, 2025
UBS Financial Services, Inc.
234.00
0%
-20.56K
-98.87%
Sep 30, 2025
RBC Dominion Securities, Inc.
358.00
0.01%
-305.00
-46.00%
Sep 30, 2025
Van Damme (Paul Joseph)
324.00
0%
-6.79K
-95.44%
Oct 17, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Date
Ex-dividend Date
Type
Ratio
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
